ProAir HFA gains pediatric asthma indication

ProAir HFA gains pediatric asthma indication
ProAir HFA gains pediatric asthma indication

Teva's ProAir HFA (albuterol sulfate inhalation aerosol) is now approved for the treatment and prevention of bronchospasm in children 4–11 years of age.

ProAir HFA has already been available for the treatment or prevention of bronchospasm in reversible obstructive airway disease and prevention of exercise-induced bronchospasm in patients ≥12 years of age.

For more information call (888) 482-9522 or visit www.ProAirHFA.com.